Molecular landscape of eyelid sebaceous gland carcinoma: A comprehensive review.
Journal
Indian journal of ophthalmology
ISSN: 1998-3689
Titre abrégé: Indian J Ophthalmol
Pays: India
ID NLM: 0405376
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
received:
16
01
2024
accepted:
25
05
2024
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
27
9
2024
Statut:
ppublish
Résumé
Eyelid sebaceous gland carcinoma (SGC) is an aggressive skin cancer characterized by a heightened risk of recurrence and metastasis. While surgical excision is the primary treatment, unraveling the molecular intricacies of SGC is imperative for advancing targeted therapeutic interventions and enhancing patient outcomes. This comprehensive review delves into the molecular landscape of eyelid SGC, emphasizing key genetic alterations, signaling pathways, epigenetic modifications, and potential therapeutic targets. Significant findings include aberrations in critical signaling pathways (β-catenin, lymphoid enhancer binding factor, hedgehog, epidermal growth factor receptor, P53, and P21WAF1) associated with SGC progression and poor prognosis. Notably, eyelid SGC manifests a distinctive mutational profile, lacking ultraviolet signature mutations in tumor protein 53 (TP53), indicating alternative mutagenic mechanisms. Next-generation sequencing identifies actionable mutations in genes such as phosphatase and tensin homolog (PTEN) and Erb-B2 receptor tyrosine kinase 2 (ERBB2), facilitating the emergence of personalized medicine approaches. Molecular chaperones, specifically X-linked inhibitor of apoptosis protein (XIAP) and BAG3, emerge as pivotal players in promoting tumor survival and proliferation. The review underscores the role of epithelial-mesenchymal transition, where regulators like E-cadherin, vimentin, and ZEB2 contribute to SGC aggressiveness. Epigenetic modifications, encompassing DNA methylation and microRNA dysregulation, further elucidate the molecular landscape. This review consolidates a comprehensive understanding of the molecular drivers of eyelid SGC, shedding light on potential therapeutic targets and providing a foundation for future investigations in diagnostic, prognostic, and personalized treatment strategies for this formidable malignancy.
Identifiants
pubmed: 39331429
doi: 10.4103/IJO.IJO_167_24
pii: 02223307-202472100-00007
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1393-1403Informations de copyright
Copyright © 2024 Copyright: © 2024 Indian Journal of Ophthalmology.
Références
Shields JA, Demirci H, Marr BP, Eagle RC, Shields CL. Sebaceous carcinoma of the eyelids: Personal experience with 60 cases. Ophthalmology 2004;111:2151–7.
Shields JA, Demirci H, Marr BP, Eagle RC, Shields CL. Sebaceous carcinoma of the ocular region: A review. Surv Ophthalmol 2005;50:103–22.
Sa HS, Rubin ML, Xu S, Ning J, Tetzlaff M, Sagiv O, et al. Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: Observations in 100 patients. Br J Ophthalmol 2019;103:980–4.
Owen JL, Kibbi N, Worley B, Kelm RC, Wang JV, Barker CA, et al. Sebaceous carcinoma: Evidence-based clinical practice guidelines. Lancet Oncol 2019;20:e699–714.
Gerring RC, Ott CT, Curry JM, Sargi ZB, Wester ST. Orbital exenteration for advanced periorbital non-melanoma skin cancer: Prognostic factors and survival. Eye Lond Engl 2017;31:379–88.
Verma S, Kumar N, Meel R, Sen S, Kashyap S, Sharma S, et al. Neoadjuvant systemic chemotherapy in sebaceous gland carcinoma of the eyelid: A retrospective study. Ocul Oncol Pathol 2021;7:251–6.
Abbas O, Mahalingam M. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: A diagnostic algorithm. J Cutan Pathol 2009;36:613–9.
Gaskin BJ, Fernando BS, Sullivan CA, Whitehead K, Sullivan TJ. The significance of DNA mismatch repair genes in the diagnosis and management of periocular sebaceous cell carcinoma and Muir-Torre syndrome. Br J Ophthalmol 2011;95:1686–90.
North JP, Golovato J, Vaske CJ, Sanborn JZ, Nguyen A, Wu W, et al. Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. Nat Commun 2018;9:1894.
Jayaraj P, Sen S, Kashyap S, Sharma A, Pushker N, Bajaj MS, et al. Does β-catenin have a role in pathogenesis of sebaceous cell carcinoma of the eyelid? Br J Ophthalmol 2011;95:284–7.
Tetzlaff MT, Curry JL, Yin V, Pattanaprichakul P, Manonukul J, Uiprasertkul M, et al. Distinct pathways in the pathogenesis of sebaceous carcinomas implicated by differentially expressed microRNAs. JAMA Ophthalmol 2015;133:1109–16.
Takeda H, Lyle S, Lazar AJF, Zouboulis CC, Smyth I, Watt FM. Human sebaceous tumours harbor inactivating mutations in LEF1. Nat Med 2006;12:395–7.
Jayaraj P, Sen S, Sharma A, Chosdol K, Kashyap S, Rai A, et al. Eyelid sebaceous carcinoma: A novel mutation in lymphoid enhancer-binding factor-1. Br J Dermatol 2015;173:811–4.
Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih IM, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: An immunohistochemical and nucleotide sequencing analysis. Mod Pathol 2011;24:1248–53.
Peterson C, Moore R, Hicks JL, Morsberger LA, De Marzo AM, Zou Y, et al. NGS Analysis confirms common TP53 and RB1 mutations, and suggests MYC amplification in ocular adnexal sebaceous carcinomas. Int J Mol Sci 2021;22:8454.
Hussain RM, Matthews JL, Dubovy SR, Thompson JM, Wang G. UV-independent p53 mutations in sebaceous carcinoma of the eyelid. Ophthal Plast Reconstr Surg 2014;30:392–5.
Xu S, Moss TJ, Laura Rubin M, Ning J, Eterovic K, Yu H, et al. Whole-exome sequencing for ocular adnexal sebaceous carcinoma suggests PCDH15 as a novel mutation associated with metastasis. Mod Pathol 2020;33:1256–63.
Jayaraj P, Sen S, Sharma A, Chosdol K, Kashyap S, Rai A, et al. Epigenetic inactivation of the E-cadherin gene in eyelid sebaceous gland carcinoma. Br J Dermatol 2012;167:583–90.
Bhardwaj M, Sen S, Sharma A, Kashyap S, Chosdol K, Pushker N, et al. ZEB2/SIP1 as novel prognostic indicator in eyelid sebaceous gland carcinoma. Hum Pathol 2015;46:1437–42.
Bhardwaj M, Sen S, Chosdol K, Bakhshi S, Pushker N, Sharma A, et al. Vimentin overexpression as a novel poor prognostic biomarker in eyelid sebaceous gland carcinoma. Br J Ophthalmol 2020;104:879–84.
Liau JY, Liao SL, Hsiao CH, Lin MC, Chang HC, Kuo KT. Hypermethylation of the CDKN2A gene promoter is a frequent epigenetic change in periocular sebaceous carcinoma and is associated with younger patient age. Hum Pathol 2014;45:533–9.
Bhardwaj M, Sen S, Chosdol K, Sharma A, Pushker N, Kashyap S, et al. miRNA-200c and miRNA-141 as potential prognostic biomarkers and regulators of epithelial-mesenchymal transition in eyelid sebaceous gland carcinoma. Br J Ophthalmol 2017;101:536–42.
Zhao H, Yang X, Liu J, Han F, Yang Z, Hu Z, et al. Overexpression of miR-651-5p inhibits ultraviolet radiation-induced malignant biological behaviors of sebaceous gland carcinoma cells by targeting ZEB2. Ann Transl Med 2022;10:517.
Zhang CL, Liu X, Jiang MX, Zhu LM, Lin TT, He YJ. [Screening of differently expressed miRNAs and the mechanism of miR-3907 in meibomian gland carcinoma]. Zhonghua Yan Ke Za Zhi Chin J Ophthalmol 2022;58:205–12.
Cicinelli MV, Kaliki S. Ocular sebaceous gland carcinoma: An update of the literature. Int Ophthalmol 2019;39:1187–97.
Jahagirdar SS, Thakre TP, Kale SM, Kulkarni H, Mamtani M. A clinicopathological study of eyelid malignancies from central India. Indian J Ophthalmol 2007;55:109–12.
Morawala A, Mohamed A, Krishnamurthy A, Jajapuram SD, Kaliki S. Sebaceous gland carcinoma: Analysis based on the 8th edition of American Joint Cancer Committee classification. Eye 2023;37:714–9.
Raza Rizvi SA, Alam MdS, Akhtar K. Eyelid sebaceous gland carcinoma: Varied presentations and reconstruction outcome. Oman J Ophthalmol 2018;11:21–7.
Kaliki S, Ayyar A, Dave TV, Ali MJ, Mishra DK, Naik MN. Sebaceous gland carcinoma of the eyelid: Clinicopathological features and outcome in Asian Indians. Eye Lond Engl 2015;29:958–63.
Bailet JW, Zimmerman MC, Arnstein DP, Wollman JS, Mickel RA. Sebaceous carcinoma of the head and neck. Case report and literature review. Arch Otolaryngol Head Neck Surg 1992;118:1245–9.
Muqit MMK, Roberts F, Lee WR, Kemp E. Improved survival rates in sebaceous carcinoma of the eyelid. Eye 2004;18:49–53.
Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer 2009;115:158–65.
Kivelä T, Asko-Seljavaara S, Pihkala U, Hovi L, Heikkonen J. Sebaceous carcinoma of the eyelid associated with retinoblastoma. Ophthalmology 2001;108:1124–8.
Rundle P, Shields JA, Shields CL, Eagle RC, Singh AD. Sebaceous gland carcinoma of the eyelid seventeen years after irradiation for bilateral retinoblastoma. Eye Lond Engl 1999;13:109–10.
Rishi K, Font RL. Sebaceous gland tumours of the eyelids and conjunctiva in the Muir-Torre syndrome: A clinicopathologic study of five cases and literature review. Ophthal Plast Reconstr Surg 2004;20:31–6.
Demirci H, Nelson CC, Shields CL, Eagle RC, Shields JA. Eyelid sebaceous carcinoma associated with Muir-Torre syndrome in two cases. Ophthal Plast Reconstr Surg 2007;23:77–9.
Hoss E, Nelson SA, Sharma A. Sebaceous carcinoma in solid organ transplant recipients. Int J Dermatol 2017;56:746–9.
Tetzlaff MT, Singh RR, Seviour EG, Curry JL, Hudgens CW, Bell D, et al. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol 2016;240:84–95.
Chauhan S, Sen S, Singh N, Sharma A, Pushker N, Kashyap S, et al. Human papillomavirus in ocular malignant tumours: A study from a tertiary eye care centre in North India. Canadian J Ophthal 2019;54:688–93.
Pe’er J. Pathology of eyelid tumours. Indian J Ophthalmol 2016;64:177.
Song A, Carter KD, Syed NA, Song J, Nerad JA. Sebaceous cell carcinoma of the ocular adnexa: Clinical presentations, histopathology, and outcomes. Ophthal Plast Reconstr Surg 2008;24:194–200.
Hayashi Y, Shima H, Kita D, Kinoshita M, Yoshida Y, Hasegawa M, et al. Intracranial extension of meibomian gland carcinoma with pagetoid changes. J Clin Neurosci 2009;16:568–70.
Shields JA, Saktanasate J, Lally SE, Carrasco JR, Shields CL. Sebaceous carcinoma of the ocular region: The 2014 Professor Winifred Mao lecture. Asia Pac J Ophthalmol (Phila) 2015;4:221–7.
Zhou C, Chai P, Xia W, Li J, Jia R, Fan X. Intraepithelial growth pattern for eyelid sebaceous carcinoma: A cohort of 214 patients from a single institution. Br J Ophthalmol 2023;107:324–30.
Plaza JA, Mackinnon A, Carrillo L, Prieto VG, Sangueza M, Suster S. Role of immunohistochemistry in the diagnosis of sebaceous carcinoma: A clinicopathologic and immunohistochemical study. Am J Dermatopathol 2015;37:809–21.
Ansai S, Arase S, Kawana S, Kimura T. Immunohistochemical findings of sebaceous carcinoma and sebaceoma: Retrieval of cytokeratin expression by a panel of anti-cytokeratin monoclonal antibodies. J Dermatol 2011;38:951–8.
Ansai S, Takeichi H, Arase S, Kawana S, Kimura T. Sebaceous carcinoma: An immunohistochemical reappraisal. Am J Dermatopathol 2011;33:579–87.
Muthusamy K, Halbert G, Roberts F. Immunohistochemical staining for adipophilin, perilipin and TIP47. J Clin Pathol 2006;59:1166–70.
Johnson JS, Lee JA, Cotton DW, Lee WR, Parsons MA. Dimorphic immunohistochemical staining in ocular sebaceous neoplasms: A useful diagnostic aid. Eye Lond Engl 1999;13:104–8.
Mulay K, White VA, Shah SJ, Honavar SG. Sebaceous carcinoma: Clinicopathologic features and diagnostic role of immunohistochemistry (including androgen receptor). Can J Ophthalmol J Can Ophtalmol 2014;49:326–32.
Cohen PR. Sebaceous carcinomas of the ocular adnexa and the Muir-Torre syndrome. J Am Acad Dermatol 1992;27:279–80.
Lynch HT, Fusaro RM, Lynch PM. Sebaceous skin lesions as clues to hereditary non-polyposis colorectal cancer. J Invest Dermatol 2006;126:2158–9.
Rajan Kd A, Burris C, Iliff N, Grant M, Eshleman JR, Eberhart CG. DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma. Am J Ophthalmol 2014;157:640–7.
Eiger-Moscovich M, Eagle RC, Shields CL, Racher H, Lally SE, Silkiss RZ, et al. Muir-Torre Syndrome associated periocular sebaceous neoplasms: Screening patterns in the literature and in clinical practice. Ocul Oncol Pathol 2020;6:226–37.
Niemann C, Unden AB, Lyle S, Zouboulis ChC, Toftgård R, Watt FM. Indian hedgehog and β-catenin signalling: Role in the sebaceous lineage of normal and neoplastic mammalian epidermis. Proc Natl Acad Sci 2003;100:11873–80.
Niemann C, Owens DM, Schettina P, Watt FM. Dual role of inactivating Lef1 mutations in epidermis: Tumour promotion and specification of tumour type. Cancer Res 2007;67:2916–21.
Kim N, Kim JE, Choung HK, Lee MJ, Khwarg SI. Expression of Shh and Wnt signalling pathway proteins in eyelid sebaceous gland carcinoma: Clinicopathologic study. Invest Ophthalmol Vis Sci 2013;54:370–7.
Na HY, Park JH, Shin SA, Lee S, Lee H, Chae H, et al. Targeted sequencing revealed distinct mutational profiles of ocular and extraocular sebaceous carcinomas. Cancers 2021;13:4810.
Muñoz-Jiménez MT, Blanco L, Ruano Y, Carrillo R, Santos-Briz Á, Riveiro-Falkenbach E, et al. TERT promoter mutation in sebaceous neoplasms. Virchows Arch Int J Pathol 2021;479:551–8.
Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, et al. Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials. Signal Transduct Target Ther 2019;4:1–39.
Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: A historical overview. Transl Oncol 2020;13:100773.
Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumour suppressors. Dev Biol 2007;302:1–12.
Zhang C, Zhu L, Liu X, Jiang M, Tang Q, Xu F, et al. MicroRNA-3907 promotes the proliferation and migration of sebaceous gland carcinoma of the eyelid by targeting thrombospondin 1. Oncol Lett 2021;22:1–10.
Bladen JC, Wang J, Sangaralingam A, Moosajee M, Fitchett C, Chelala C, et al. MicroRNA and transcriptome analysis in periocular sebaceous gland carcinoma. Sci Rep 2018;8:7531.
Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, et al. miR-141 and miR-200a act on ovarian tumourigenesis by controlling oxidative stress response. Nat Med 2011;17:1627–35.
Hirano T, Yunoki T, Furusawa Y, Tabuchi Y, Hayashi A. Bioinformatics analysis of the microRNA-mRNA network in sebaceous gland carcinoma of the eyelid. Mol Med Rep 2021;23:1–1.
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105–11.
Kim N, Choung HK, Lee MJ, Khwarg SI, Kim JE. Cancer stem cell markers in eyelid sebaceous gland carcinoma: High expression of ALDH1, CD133, and ABCG2 correlates with poor prognosis. Invest Ophthalmol Vis Sci 2015;56:1813–9.
Horst D, Scheel SK, Liebmann S, Neumann J, Maatz S, Kirchner T, et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 2009;219:427–34.
Gopinatha Pillai MS, Aiswarya SU, Keerthana CK, Rayginia TP, Anto RJ. Targeting receptor tyrosine kinase signalling: Avenues in the management of cutaneous squamous cell carcinoma. iScience 2023;26:106816.
Chen S, Qiu Y, Guo P, Pu T, Feng Y, Bu H. FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis. Oncol Lett 2018;15:8206–14.
Lee MJ, Kim N, Choung HK, Choe JY, Khwarg SI, Kim JE. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target. J Cancer Res Clin Oncol 2016;142:125–33.
Erovic BM, Al Habeeb A, Harris L, Goldstein DP, Kim D, Ghazarian D, et al. Identification of novel target proteins in sebaceous gland carcinoma. Head Neck 2013;35:642–8.
Williams GH, Stoeber K. The cell cycle and cancer. J Pathol 2012;226:352–64.
Yunoki T, Hirano T, Tabuchi Y, Furusawa Y, Torigoe M, Nakajima T, et al. CDKN2A, CDK1, and CCNE1 overexpression in sebaceous gland carcinoma of eyelid. Int Ophthalmol 2020;40:343–50.
Kim N, Kim JE, Choung HK, Lee MJ, Khwarg SI. Expression of cell cycle regulatory proteins in eyelid sebaceous gland carcinoma: Low p27 expression predicts poor prognosis. Exp Eye Res 2014;118:46–52.
Tu H, Costa M. XIAP’s profile in human cancer. Biomolecules 2020;10:1493.
Jayaraj P, Sen S, Dhanaraj PS, Jhajhria R, Singh S, Singh VK. Immunohistochemical expression of X-linked inhibitor of apoptosis in eyelid sebaceous gland carcinoma predicts a worse prognosis. Indian J Ophthalmol 2017;65:1109–13.
Thomas CJ, Wood GC, Marks VJ. Mohs micrographic surgery in the treatment of rare aggressive cutaneous tumours: The Geisinger experience. Dermatol Surg 2007;33:333–9.
Tyers AG. Orbital exenteration for invasive skin tumours. Eye Lond Engl 2006;20:1165–70.
Savar A, Oellers P, Myers J, Prieto VG, Torres-Cabala C, Frank SJ, et al. Positive sentinel node in sebaceous carcinoma of the eyelid. Ophthal Plast Reconstr Surg 2011;27:e4–6.
Vuthaluru S, Pushker N, Lokdarshi G, Kumar R, Bajaj MS, Kashyap S, et al. Sentinel lymph node biopsy in malignant eyelid tumour: Hybrid single photon emission computed tomography/computed tomography and dual dye technique. Am J Ophthalmol 2013;156:43–49.
Hata M, Koike I, Omura M, Maegawa J, Ogino I, Inoue T. Noninvasive and curative radiation therapy for sebaceous carcinoma of the eyelid. Int J Radiat Oncol Biol Phys 2012;82:605–11.
Takagawa Y, Tamaki W, Suzuki S, Inaba K, Murakami N, Takahashi K, et al. Radiotherapy for localized sebaceous carcinoma of the eyelid: A retrospective analysis of 83 patients. J Radiat Res (Tokyo) 2019;60:622–9.
Deo SVS, Shukla NK, Singh M, Jha D, Khanna P, Kallianpur A. Locally advanced sebaceous cell carcinoma (T3) of eyelid: Incidence and pattern of nodal metastases and combined modality management approach. Orbit Amst Neth 2012;31:150–4.
Mehta A, Kaur M, Singh M, Gupta P. Commentary: Cryotherapy and the sebaceous glands. Indian J Ophthalmol 2022;70:633–4.
Russell HC, Chadha V, Lockington D, Kemp EG. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: A 10-year review of treatment outcomes and complications. Br J Ophthalmol 2010;94:1316–21.
Shields CL, Naseripour M, Shields JA, Eagle RC. Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma. Ophthalmology 2002;109:2129–33.
Kaliki S, Ayyar A, Nair AG, Mishra DK, Reddy VAP, Naik MN. Neoadjuvant systemic chemotherapy in the management of extensive eyelid sebaceous gland carcinoma: A study of 10 Cases. Ophthal Plast Reconstr Surg 2016;32:35–9.
Priyadarshini O, Biswas G, Biswas S, Padhi R, Rath S. Neoadjuvant chemotherapy in recurrent sebaceous carcinoma of eyelid with orbital invasion and regional lymphadenopathy. Ophthal Plast Reconstr Surg 2010;26:366–8.
Domingo-Musibay E, Murugan P, Giubellino A, Sharma S, Steinberger D, Yuan J, et al. Near complete response to pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma. J Immunother Cancer 2018;6:58.
Kodali S, Tipirneni E, Gibson PC, Cook D, Verschraegen C, Lane KA. Carboplatin and pembrolizumab chemoimmunotherapy achieves remission in recurrent, metastatic sebaceous carcinoma. Ophthal Plast Reconstr Surg 2018;34:e149–51.
Gravbrot N, Gilbert-Gard K, Mehta P, Ghotmi Y, Banerjee M, Mazis C, et al. Therapeutic monoclonal antibodies targeting immune checkpoints for the treatment of solid tumours. Antibodies 2019;8:51.
Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet Lond Engl 2021;398:1002–14.
Lehrer EJ, Kowalchuk RO, Gurewitz J, Bernstein K, Kondziolka D, Niranjan A, et al. Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases. Int J Radiat Oncol Biol Phys 2023;116:858–68.
Singh L, Singh MK, Rizvi MA, Pushker N, Bakhshi S, Sen S, et al. Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma. Br J Ophthalmol 2021;105:48–56.
Jayaraj P, Sen S. Evaluation of PD-L1 and PD-1 expression in aggressive eyelid sebaceous gland carcinoma and its clinical significance. Indian J Ophthalmol 2019;67:1983–7.